Compare Abbott Laboratories (ABT) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Wipro Limited — how do they compare? Abbott Laboratories trades at $108.87 (market cap $187.95B), while Wipro Limited trades at $1.94 (market cap $19.07B). The key difference: Abbott Laboratories is far larger — about 9.9× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (4.4%). Which is the better fit depends on your goals.
| ABT | WIT | |
|---|---|---|
Market Cap | $187.95B | $19.07B |
Sector | Health | Technology |
52-Week High | $136.62 | $3.06 |
52-Week Low | $82.57 | $1.78 |
Enterprise Value | $214.96B | $17.16B |
Dividend Yield | 2.32% | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
WIT trades at $1.99, down 1.49% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains solid fundamentals with a P/E of 14.9, net income margin of 13.92%, and strong cash flow generation of $169.4B in 2025. Recent news highlights Wipro's strategic AI partnerships with Databricks and ServiceNow to drive enterprise transformation.
WIT presents a cautious opportunity with reasonable valuation metrics and strategic AI investments, though recent earnings misses and mixed analyst sentiment (19% buy, 48% hold) suggest near-term headwinds. Key risks include competitive IT services pressure and client spending uncertainty, while institutional ownership trends and dividend payments provide some stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
